Glenmark Pharma
₹2,265
- Market Cap
- ₹62,829Cr.
- P/E Ratio
- 20.1
- P/B Ratio
- 6.09
- EPS (TTM)
- ₹112.69
- Div Yield
- 0.22%
- ROCE
- 39.8%
- ROE
- 23.6%
52W Low: ₹1,79352W High: ₹2,538
At a glance
- Sales have grown 14.0% a year over three years.
- Debt is 0.06× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Glenmark_Pharma — Price
Interval
Style
Failed: 503
Scorecard
Market: risk-off · breadth 374/8Minerviniuptrend checks met
64RS Rankvs all stocks, 1–99
bullRSI Regimemomentum range
34 ▲Trend (ADX)trend strength
0/4CAN SLIMprice & volume checks
downSupertrendprice vs trailing line
downVolume Flowbuying vs selling volume
Factual technical classifications from price/volume data — research signals, not investment advice. Hover or tap any badge for what it means.
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
P/E 20.1P/E: 20.1 | P/B: 6.09Growth
GrowingSales CAGR — 3Y: 14% · 1Y: 33%Profitability
High MarginROCE: 39.8% | ROE: 23.6%Key Metrics
Valuation
PEG Ratio 0.33
Price / Sales 3.54x
Price / FCF 30.1x
Book Value ₹372
Margins & returns
Operating Margin 27%
Net Margin 10.1%
Return on Assets 9.0%